Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Other Non-Current Liabilities (2018 - 2023)

Historic Other Non-Current Liabilities for China Pharma Holdings (CPHI) over the last 12 years, with Q1 2023 value amounting to $2.2 million.

  • China Pharma Holdings' Other Non-Current Liabilities changed N/A to $2.2 million in Q1 2023 from the same period last year, while for Mar 2023 it was $2.2 million, marking a year-over-year change of. This contributed to the annual value of $2.4 million for FY2022, which is 2685.03% up from last year.
  • China Pharma Holdings' Other Non-Current Liabilities amounted to $2.2 million in Q1 2023.
  • China Pharma Holdings' 5-year Other Non-Current Liabilities high stood at $3.1 million for Q2 2021, and its period low was $1.7 million during Q3 2021.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $2.4 million (2022), whereas its average is $2.3 million.
  • Per our database at Business Quant, China Pharma Holdings' Other Non-Current Liabilities crashed by 3144.04% in 2021 and then surged by 2685.03% in 2022.
  • Quarter analysis of 5 years shows China Pharma Holdings' Other Non-Current Liabilities stood at $2.4 million in 2019, then increased by 14.44% to $2.7 million in 2020, then tumbled by 31.44% to $1.9 million in 2021, then increased by 26.85% to $2.4 million in 2022, then decreased by 9.15% to $2.2 million in 2023.
  • Its Other Non-Current Liabilities stands at $2.2 million for Q1 2023, versus $2.4 million for Q4 2022 and $1.9 million for Q4 2021.